BIOMAT Database Logo BIOMAT Database Logo

Effects of YM175, a new-generation bisphosphonate, on hypercalcemia induced by tumor-derived bone resorbing factors in rats. 1998

K Takahashi, and A Shirahata, and S Fukushima, and S Kokubo, and K Teramura, and S Usuda
Pharmacology Laboratories, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tokyo, Japan.

YM175 (disodium cycloheptylaminomethylenediphosphonate monohydrate) is a new-generation bisphosphonate with stronger inhibitory activity on bone resorption than first-generation bisphosphonates. In the present study, the effect of YM175 on hypercalcemia induced in rats by single administration of either parathyroid hormone-related protein (PTHrP) or concomitant administration of PTHrP and interleukin 1beta (IL-1beta) was investigated. YM175 (0.01-1 mg/kg, i.v.) inhibited the increase in serum free calcium concentration induced by continuous administration of PTHrP alone (3 microg/rat/day, s.c., 7 days) dose-dependently. The inhibitory effect of YM175 appeared the day after administration and remained 3 days after administration. The effect of YM175 reached a maximum 2 days after administration, at which time the ED50 value of YM175 was calculated to be 0.041 mg/kg, i.v., revealing a potency approximately 50- and 10-fold stronger than those of either pamidronate or alendronate, respectively. In contrast, elcatonin (1-10 units/kg, s.c.) only transiently inhibited PTHrP-induced free calcium increase. YM175 (0.1-3 mg/kg, i.v.) also inhibited the increase in the serum free calcium concentration induced by continuous concomitant administration of both PTHrP and IL-1beta in a dose-dependent manner. These results indicated that YM175 is expected to be a useful drug for hypercalcemia associated with malignant tumors due to its efficacy and range of effect.

UI MeSH Term Description Entries
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D008297 Male Males
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D001862 Bone Resorption Bone loss due to osteoclastic activity. Bone Loss, Osteoclastic,Osteoclastic Bone Loss,Bone Losses, Osteoclastic,Bone Resorptions,Loss, Osteoclastic Bone,Losses, Osteoclastic Bone,Osteoclastic Bone Losses,Resorption, Bone,Resorptions, Bone
D004164 Diphosphonates Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents. Bisphosphonate,Bisphosphonates
D006934 Hypercalcemia Abnormally high level of calcium in the blood. Milk-Alkali Syndrome,Hypercalcemias,Milk Alkali Syndrome,Syndrome, Milk-Alkali
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats

Related Publications

K Takahashi, and A Shirahata, and S Fukushima, and S Kokubo, and K Teramura, and S Usuda
Inhibitory effects of bisphosphonate (YM175) on bone resorption induced by a metastatic bone tumor.
January 1996, Bone,
K Takahashi, and A Shirahata, and S Fukushima, and S Kokubo, and K Teramura, and S Usuda
Intramembranous and endochondral bone changes induced by a new bisphosphonate (YM175) in the beagle dog.
January 1994, Toxicologic pathology,
K Takahashi, and A Shirahata, and S Fukushima, and S Kokubo, and K Teramura, and S Usuda
Pharmacokinetics of YM175, a new bisphosphonate, in rats and dogs.
November 1995, Drug metabolism and disposition: the biological fate of chemicals,
K Takahashi, and A Shirahata, and S Fukushima, and S Kokubo, and K Teramura, and S Usuda
Inhibition by a new bisphosphonate (YM175) of bone resorption induced by the MBT-2 tumour of mice.
May 1993, British journal of cancer,
K Takahashi, and A Shirahata, and S Fukushima, and S Kokubo, and K Teramura, and S Usuda
[Tumor-induced hypercalcemia. Review of bisphosphonate treatment].
July 2001, La Revue de medecine interne,
K Takahashi, and A Shirahata, and S Fukushima, and S Kokubo, and K Teramura, and S Usuda
Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients.
July 1994, The Journal of clinical endocrinology and metabolism,
K Takahashi, and A Shirahata, and S Fukushima, and S Kokubo, and K Teramura, and S Usuda
Determination of a new bisphosphonate, YM175, in plasma, urine and bone by high-performance liquid chromatography with electrochemical detection.
December 1992, Journal of chromatography,
K Takahashi, and A Shirahata, and S Fukushima, and S Kokubo, and K Teramura, and S Usuda
Prevention of bone loss by bisphosphonate YM175 in ovariectomized dogs with dietary calcium restriction.
July 1996, Japanese journal of pharmacology,
K Takahashi, and A Shirahata, and S Fukushima, and S Kokubo, and K Teramura, and S Usuda
A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate.
December 1986, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,
K Takahashi, and A Shirahata, and S Fukushima, and S Kokubo, and K Teramura, and S Usuda
Polymethylmethacrylate-induced release of bone-resorbing factors.
December 1989, The Journal of bone and joint surgery. American volume,
Copied contents to your clipboard!